Peritoneal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Seagen, Mersana, ImmunoGen, Elucida, Rhizen, Green3Bio, Oncoinvent, OncoMed

Peritoneal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Seagen, Mersana, ImmunoGen, Elucida, Rhizen, Green3Bio, Oncoinvent, OncoMed
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 60+ key pharma and biotech companies are working on 60+ pipeline drugs in the Peritoneal Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Peritoneal Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Peritoneal Cancer Market. 

The Peritoneal Cancer Pipeline report embraces in-depth commercial, regulatory, and Peritoneal Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Peritoneal Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Peritoneal Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Peritoneal Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Peritoneal Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Peritoneal Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Peritoneal Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Peritoneal Cancer therapeutic market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Peritoneal Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Peritoneal Cancer Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight

Peritoneal Cancer Therapeutics Market Outlook

There are approx. 60+ key companies developing therapies for Peritoneal Cancer. Currently, ImmunoGen is leading the therapeutics market with its Peritoneal Cancer drug candidates in the most advanced stage of clinical development.

Peritoneal Cancer Companies Actively Working in the Therapeutic Market Include:

  • Shattuck Labs, Inc.

  • Corcept Therapeutics

  • Seagen

  • Mersana Therapeutics

  • IMPACT Therapeutics

  • ImmunoGen

  • LintonPharm Co.,Ltd.

  • Sutro Biopharma, Inc.

  • Elucida Oncology

  • Bio-Path Holdings

  • Clover BiopharmaceuticalAUS Pty Ltd

  • Rhizen Pharmaceuticals SA

  • Oncoinvent

  • OncoMed Pharmaceuticals, Inc.

  • Ipsen

  • Green3Bio

And Many Other

Emerging and Marketed Peritoneal Cancer Drugs Covered in the Report Include:

  • Luvelta (STRO-002): Sutro Biopharma, Inc.

  • IMGN151: ImmunoGen

  • Catumaxomab: LintonPharm Co., Ltd.

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Peritoneal Cancer Companies Working in the Market:

https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Peritoneal Cancer Treatment Patterns

4. Peritoneal Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Peritoneal Cancer Late Stage Products (Phase-III)

7. Peritoneal Cancer Mid-Stage Products (Phase-II)

8. Peritoneal Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Peritoneal Cancer Discontinued Products

13. Peritoneal Cancer Product Profiles

14. Major Peritoneal Cancer Companies in the Market

15. Key Products in the Peritoneal Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Peritoneal Cancer Unmet Needs

18. Peritoneal Cancer Future Perspectives

19. Peritoneal Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports By DelveInsight

Acute Respiratory Distress Syndrome (ARDS) Market

Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the ARDS market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: